Multi-omics analysis revealed significant metabolic changes in brain cancer cells treated with paclitaxel and/or topotecan

Multi-omics analysis revealed significant metabolic changes in brain cancer cells treated with paclitaxel and/or topotecan

Glioblastoma (GBM) stands as the most common primary malignant brain tumor. Despite the best standard therapies, GBM survivors have a brief survival time, about 24 months on average. The treatment is troublesome because the cancer cells may not respond well to specific therapies as they grow within...

Full description

Saved in:
Bibliographic Details
Main Authors: Ahlam M. Semreen, Leen Oyoun Alsoud, Mohammad H. Semreen, Munazza Ahmed, Hamza M. Al-Hroub, Raafat El-Awady, Wafaa S. Ramadan, Ahmad Abuhelwa, Yasser Bustanji, Nelson C. Soares, Karem H. Alzoubi
Format: Article
Language:English
Published: Elsevier 2024-11-01
Series:Heliyon
Subjects:
Proteomics
Metabolomics
Brain Cancer
Therapy
Drug treatment
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024154515
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items